# Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects

> **NCT00648544** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 44 (actual)

## Conditions studied

- Therapeutic Equivalency

## Interventions

- **DRUG:** Pravastatin
- **DRUG:** Pravastatin

## Key facts

- **NCT ID:** NCT00648544
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2003-07
- **Final completion:** 2003-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648544, "Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00648544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*